Due Process in Reproductive Health: FDA Must Hear Opposition to Contraceptives

The Supreme Court has clarified that the Food and Drug Administration (FDA) cannot simply invoke its "regulatory power" to bypass the constitutional requirement of due process. In Alliance for the Family Foundation Philippines, Inc. v. Garin (G.R. No. 217872, April 26, 2017), the Court denied the government's motion for reconsideration and reaffirmed its earlier ruling that the FDA must conduct hearings and allow oppositors to be heard before certifying contraceptive drugs and devices as non-abortifacient. The ruling is a significant reminder that even specialized administrative agencies must respect fundamental rights, especially in matters involving reproductive health and the right to life.

The Case at a Glance

The petitioners, led by the Alliance for the Family Foundation Philippines, Inc. (ALFI), opposed the FDA's registration, re-certification, procurement, and distribution of certain contraceptive drugs and devices, including Implanon and Implanon NXT. They argued that these products might have abortifacient properties—meaning they could prevent a fertilized ovum from implanting in the womb—which would violate Republic Act No. 10354, the Responsible Parenthood and Reproductive Health Act of 2012 (RH Law).

The petitioners filed oppositions with the FDA, but the agency did not act on them. Instead, the FDA proceeded with the certification and distribution of the contraceptives. The petitioners then went to the Supreme Court, which initially ruled in their favor and remanded the case to the FDA. The government, through the Office of the Solicitor General, sought partial reconsideration, arguing that the FDA's actions were done in the exercise of its regulatory power and, therefore, did not require notice and hearing.

The Issue: Does Regulatory Power Excuse Due Process?

The central question was whether the FDA's issuance of certificates of product registration (CPR) for contraceptives—an act the government classified as "regulatory"—required compliance with the twin requirements of due process: notice and hearing.

The government argued that the FDA's functions were carefully delineated under the Implementing Rules and Regulations of R.A. No. 9711 (the FDA Act of 2009). It claimed that only the Director-General exercised quasi-judicial powers, which require notice and hearing, while the FDA's regulatory functions did not. The government further argued that the standards of procedural due process laid down in Ang Tibay v. CIR were inapplicable because the FDA's findings on abortifacient properties were scientific matters beyond the competence of courts.

The Ruling: Due Process Cannot Be Set Aside

The Supreme Court rejected the government's arguments. The Court explained that administrative bodies exercise two fundamental powers: quasi-legislative and quasi-judicial. While quasi-legislative power—the authority to adopt rules of general application—does not ordinarily require notice and hearing, quasi-judicial power—the authority to determine facts and apply the law to specific parties—requires the observance of due process.

The Court held that the FDA's act of certifying contraceptive drugs is not purely regulatory in the sense the government claimed. Citing Professor Freund's classification, the Court noted that "enabling powers"—which include the issuance of licenses and permits—are a subcategory of quasi-judicial power. These powers require compliance with notice and hearing.

More fundamentally, the Court emphasized that the Constitution mandates that no person shall be deprived of life, liberty, or property without due process of law. This guarantee is unqualified by the type of proceeding involved. When there is grave abuse of discretion—such as denying a party the right to be heard—the Court has the power of judicial review, regardless of whether the agency calls its act "regulatory."

The Court also found that the FDA's own procedures, as outlined by the government, were deficient. The procedure only allowed public comments for re-certification cases, not for first-time certifications. Moreover, if the FDA could ignore oppositions, then its requirement to post lists for public comment would be a meaningless exercise.

The Ang Tibay Standards Apply

The Court reiterated the cardinal rights of parties in administrative proceedings, first laid down in Ang Tibay v. CIR:

1. The right to a hearing, including the right to present one's case and submit evidence;
2. The tribunal must consider the evidence presented;
3. The decision must have something to support itself;
4. The evidence must be substantial;
5. The decision must be based on evidence presented at the hearing or contained in the record and disclosed to the parties;
6. The tribunal must act on its own independent consideration of the law and facts; and
7. The decision must show the issues involved and the reasons for the ruling.

The Court clarified that due process does not require a trial-type hearing. What matters is that parties are given a fair and reasonable opportunity to explain their sides and present supporting evidence. In the FDA context, "substantial evidence" means the "best scientific evidence available," including meta-analyses, systematic reviews, and recommendations of international medical organizations.

Practical Takeaways

• Administrative agencies cannot use labels to avoid due process. Whether an act is called "regulatory" or "quasi-judicial," the constitutional right to be heard applies when the agency determines the rights and liabilities of specific parties.
• Oppositions must be acted upon. An agency that invites public comments or oppositions cannot simply ignore them. It must consider the evidence presented and explain its decision.
• Due process is flexible but real. A formal trial-type hearing is not required, but parties must have a genuine opportunity to present their case and rebut contrary evidence.
• Courts can review scientific findings. The mere presence of technical or scientific issues does not oust the courts of jurisdiction, especially when constitutional rights are at stake.
• The FDA's mandate continues. The ruling did not stop the FDA from testing and inspecting drugs generally. It only enjoined the certification and distribution of the specific contraceptives subject to the petitioners' opposition until due process is observed.

This article is general information and not legal advice. For your specific situation, consult a lawyer or ask ASG Legal AI.